A Phase 1/2 interventional study of Gilteritinib in Advanced Solid Tumors and Acute Myeloid Leukemia, sponsored by Astellas Pharma Global Development, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-19.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.
Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 29th largest by enrollment, is one of 3 that started in 2016, is one of 8 in phase 1/2, and was the 6th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14–70
Technische Universität Dresden · Sites in Germany
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 14+
French Innovative Leukemia Organisation · Sites in France
Ages 18+
By country, each count listing its studies:
gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 16 · Phase 3 10
First in 2013; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 97 across the 31 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astellas Pharma Global Development, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
22 studies in Leukemia, Myeloid, Acute by Astellas Pharma Inc: none open now, 1 under way, none of them phase 3. Of 19 finished, 11 (58%) have results posted.
Among the 22 studies in Leukemia, Myeloid, Acute by Astellas Pharma Inc, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2016, is one of 7 in phase 1/2, and was the 7th registered.
Astellas Pharma Inc’s Leukemia, Myeloid, Acute studies by the year they started, since 2006.
1 of the studies testing gilteritinib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05024552H. Lee Moffitt Cancer Center and Research InstituteVyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML | 2027-02-15 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Astellas Pharma Inc’s 22 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to provide access to continued treatment for those who participated in other Astellas sponsored ASP2215 trials that completed the primary analysis and, had the potential to continue to derive clinical benefit from the treatment with ASP2215, and who did not meet any of the study discontinuation criteria in the present study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subject must either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received gilteritinib 40 milligrams (mg) dose (one tablet of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
Drug: Gilteritinib
Participants received gilteritinib 80 mg dose (two tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
Drug: Gilteritinib
Participants received gilteritinib 120 mg dose (three tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
Drug: Gilteritinib
Participants received gilteritinib 200 mg dose (five tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
Drug: Gilteritinib
oral tablet
Also known as: ASP2215
Number of Participants With Adverse Events
AE was defined as any untoward medical occurrence in a participant administered a study drug or has undergone study procedures and which did not necessarily have a causal relationship with this treatment. An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, Electrocardiography (ECG) data, and physical exam) was defined as an AE only if the abnormality induces clinical signs or symptoms or requires active intervention or requires interruption or discontinuation of study medication or the abnormality or investigational value is clinically significant in the opinion of the investigator.
Time frame: From first dose of study drug up to 30 days after last dose of study drug (median treatment duration was 811.0 days, minimum of 43 days and maximum of 1067 days)
Eastern Cooperative Oncology Group (ECOG) Performance Status at End Of Treattment Visit (EOT)
ECOG performance status was used to assess participants disease progression, and ability to carry out the daily living activities. The participants were graded on a scale of 0 to 5 where 0 = fully active, able to carry on all predisease performance without restriction; 1 = restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = capable of only limited self-care,confined to bed or chair more than 50% of waking hours; 4 = completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; 5 = Dead. Number of participants with ECOG performance status was reported.
Time frame: EOT Visit (30 days post-last dose, maximum treatement duration of 1067 days)
Participants from previosuly conducted ASP2215 trial were recruited to receive gilteritinib at a dose specified at the time of their end of study visit in the previous ASP2215 study.
| Milestone | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg |
|---|---|---|---|---|
| Started | 2 | 3 | 3 | 1 |
| Completed | 0 | 1 | 0 | 0 |
| Not completed | 2 | 2 | 3 | 1 |
| Withdrew: Participant transitioned to commercial drug | 1 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 0 |
| Withdrew: Disease progression | 0 | 1 | 0 | 0 |
AE was defined as any untoward medical occurrence in a participant administered a study drug or has undergone study procedures and which did not necessarily have a causal relationship with this treatment. An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, Electrocardiography (ECG) data, and physical exam) was defined as an AE only if the abnormality induces clinical signs or symptoms or requires active intervention or requires interruption or discontinuation of study medication or the abnormality or investigational value is clinically significant in the opinion of the investigator.
| Participants | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg |
|---|---|---|---|---|
| Number of Participants With Adverse Events | 2 | 3 | 3 | 1 |
ECOG performance status was used to assess participants disease progression, and ability to carry out the daily living activities. The participants were graded on a scale of 0 to 5 where 0 = fully active, able to carry on all predisease performance without restriction; 1 = restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = capable of only limited self-care,confined to bed or chair more than 50% of waking hours; 4 = completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; 5 = Dead. Number of participants with ECOG performance status was reported.
| Participants | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg |
|---|---|---|---|---|
| Grade 0 | 2 | 0 | 0 | 0 |
| Grade 1 | 0 | 3 | 0 | 1 |
| Grade 2 | 0 | 0 | 1 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 |
Collected over From first dose of study drug up to 30 days after last dose of study drug (median treatment duration was 811.0 days, minimum of 43 days and maximum of 1067 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gilteritinib 40 mg | 0/2 (0%) | 2/2 (100%) | 2/2 (100%) |
| Gilteritinib 80 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Gilteritinib 120 mg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Gilteritinib 200 mg | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg |
|---|---|---|---|---|
| AppendicitisInfections and infestations | 1/2 | 0/3 | 0/3 | 0/1 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/2 | 0/3 | 0/3 | 0/1 |
| Obstructive pancreatitisGastrointestinal disorders | 0/2 | 0/3 | 1/3 | 0/1 |
| PyrexiaGeneral disorders | 0/2 | 0/3 | 1/3 | 0/1 |
| Respiratory syncytial virus infectionInfections and infestations | 0/2 | 0/3 | 1/3 | 0/1 |
| Staphylococcal bacteraemiaInfections and infestations | 0/2 | 0/3 | 1/3 | 0/1 |
| Blood creatine phosphokinase increasedInvestigations | 0/2 | 1/3 | 0/3 | 0/1 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/2 | 0/3 | 1/3 | 0/1 |
| MyositisMusculoskeletal and connective tissue disorders | 0/2 | 1/3 | 0/3 | 0/1 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/2 | 0/3 | 1/3 | 0/1 |
| Event | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/2 | 1/3 | 2/3 | 1/1 |
| ToothacheGastrointestinal disorders | 0/2 | 0/3 | 0/3 | 1/1 |
| FatigueGeneral disorders | 1/2 | 1/3 | 0/3 | 1/1 |
| PainGeneral disorders | 0/2 | 0/3 | 0/3 | 1/1 |
| PyrexiaGeneral disorders | 0/2 | 0/3 | 1/3 | 1/1 |
| COVID-19Infections and infestations | 0/2 | 0/3 | 0/3 | 1/1 |
| InfluenzaInfections and infestations | 1/2 | 0/3 | 1/3 | 1/1 |
| SinusitisInfections and infestations | 1/2 | 0/3 | 0/3 | 1/1 |
| Foot fractureInjury, poisoning and procedural complications | 0/2 | 0/3 | 1/3 | 1/1 |
| WoundInjury, poisoning and procedural complications | 0/2 | 0/3 | 0/3 | 1/1 |
The analysis population was the safety analysis set (SAF), which consisted of all participants who received at least 1 dose of study drug.
| Age, Continuous(Years) | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 47.5 ± 17.7 | 41 ± 17.5 | 55.7 ± 12.1 | 31.0 | 46.2 ± 15.0 |
| Sex: Female, Male(Participants) | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Total |
|---|---|---|---|---|---|
| Female | 2 | 1 | 2 | 1 | 6 |
| Male | 0 | 2 | 1 | 0 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 2 | 2 | 3 | 1 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 2 | 3 | 3 | 1 | 9 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Total |
|---|---|---|---|---|---|
| Grade 0 | 1 | 2 | 0 | 1 | 4 |
| Grade 1 | 1 | 1 | 3 | 0 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Ran from May 2016 to primary completion in Jul 2020, 50 months.
Results were first posted in Aug 2021, 1 year after primary completion.
Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 50 months is below that.
Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gilteritinib
Astellas Pharma Global Development, Inc. →